INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain5h ago

Most active filers · 30d

  1. 01FWFogarty Patrick W0B / 206S206 trades$1.10M
  2. 02Kurtz George0B / 202S202 trades$48.06M
  3. 03SPSaba Capital Management, L.P.67B / 19S · 11 late86 trades$22.22M
  4. 04NYNissan Yitzhak82B / 0S · 79 late82 trades$2.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SJSheena Jonathan0B / 45S45 trades$3.01M
  9. 09CMCannon-Brookes Michael35B / 0S35 trades$11.72M
  10. 10SLSpeiser Michael L0B / 35S35 trades$14.00M

Cluster activity · 60d

  1. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  2. BUYMTDRMatador Resources CoNov 5 – Nov 189 insiders$1.02M
  3. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  4. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  5. SELLMGNIMAGNITE, INC.Nov 5 – Nov 198 insiders$2.81M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  8. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M

Form 4 transactions

74,191 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
BG
Brower Nathan GEVP, General Counsel
NATRNATURES SUNSHINE PRODUCTS INC
Tax withholding
F$9,625
700 sh
Nov 4, 2025Nov 6, 2025
Page 1847 of 1855
← PrevNext →
traded Nov 4, 2025
+2d
SEC Form 4

Evidence

9
CL
Clifford Katherine LeeChief Leadership & HR Officer
ACNAccenture plc
Grant or award
A$16K
66 sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC Form 4

Evidence

9
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$280K
12.5K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

9
BJ
Beraud JillDirector
LEVILEVI STRAUSS & CO
Grant or award
A—
101 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

9
MJ
McCormick Christopher JDirector
LEVILEVI STRAUSS & CO
Grant or award
A—
221 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

9
YJ
Yates Bryant JEVP & President, Europe
NATRNATURES SUNSHINE PRODUCTS INC
Tax withholding
F$11K
780 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

9
YJ
Yates Bryant JEVP & President, Europe
NATRNATURES SUNSHINE PRODUCTS INC
Option exercise
M—
1,224 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

9
BG
Brower Nathan GEVP, General Counsel
NATRNATURES SUNSHINE PRODUCTS INC
Option exercise
M—
1,008 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

8
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$208K
40.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

7
LK
Lusk KirkChief Financial Officer
HRTGHeritage Insurance Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$482K
19.9K sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC Form 4

Evidence

7
WF
Widman FredrikVP Corporate Controller
ISRGINTUITIVE SURGICAL INC
Option exercise · 10b5-1 plan
M$9,454
159 sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC Form 4

Evidence

6
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$56K
6,250 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

5
HS
Hacker SeverinDirector, Chief Tech Officer, Co-Founder, 10% Owner
DUOLDuolingo, Inc.
Open-market sale · 10b5-1 plan
SELL$43K
165 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

5
LK
Lusk KirkChief Financial Officer
HRTGHeritage Insurance Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$1,704
71 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

5
KC
KTR Management Company, LLC10% Owner
SEISolaris Energy Infrastructure, Inc.
Derivative conversion
C—
2.11M sh
Nov 6, 2025Nov 6, 2025
traded Nov 6, 2025
+0dSEC Form 4

Evidence

5
MJ
Maetzold Derek JDirector, Pres. & Chief Exec. Officer
CSTLCASTLE BIOSCIENCES INC
Open-market sale · 10b5-1 plan
SELL$7,375
237 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

4
Huffman Steve LaddDirector, CEO & President, 10% Owner
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$732K
3,873 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

4
MJ
Maetzold Derek JDirector, Pres. & Chief Exec. Officer
CSTLCASTLE BIOSCIENCES INC
Open-market sale · 10b5-1 plan
SELL$85K
2,678 sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC Form 4

Evidence

4
Huffman Steve LaddDirector, CEO & President, 10% Owner
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$478K
2,500 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

4
Huffman Steve LaddDirector, CEO & President, 10% Owner
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$815K
4,333 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

4
Huffman Steve LaddDirector, CEO & President, 10% Owner
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$609K
3,205 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

3
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

3
HS
Hacker SeverinDirector, Chief Tech Officer, Co-Founder, 10% Owner
DUOLDuolingo, Inc.
Derivative conversion · 10b5-1 plan
C—
10.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

3
HS
Hacker SeverinDirector, Chief Tech Officer, Co-Founder, 10% Owner
DUOLDuolingo, Inc.
Derivative conversion · 10b5-1 plan
C—
10.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

2
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Gift · 10b5-1 plan
G—
20.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
15.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

0
MA
Mahdessian AraDirector, Chief Executive Officer
TTANServiceTitan, Inc.
Derivative conversion · 10b5-1 plan
C—
14.3K sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC Form 4

Evidence

0
CK
Choudary Kiran KumarChief Financial Officer
RBRKRubrik, Inc.
Option exercise · 10b5-1 plan
M—
2,000 sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC Form 4

Evidence

0
Huffman Steve LaddDirector, CEO & President, 10% Owner
RDDTReddit, Inc.
Option exercise · 10b5-1 plan
M—
18.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

0
DA
Denton Sheila A.EVP & General Counsel
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M$35K
598 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

0
Huffman Steve LaddDirector, CEO & President, 10% Owner
RDDTReddit, Inc.
Option exercise · 10b5-1 plan
M—
18.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

0
CK
Choudary Kiran KumarChief Financial Officer
RBRKRubrik, Inc.
Option exercise · 10b5-1 plan
M—
2,000 sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC Form 4

Evidence

0
DA
Denton Sheila A.EVP & General Counsel
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M—
598 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
12.5K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

0
MA
Mahdessian AraDirector, Chief Executive Officer
TTANServiceTitan, Inc.
Derivative conversion · 10b5-1 plan
C—
46.5K sh
Nov 6, 2025Nov 6, 2025
traded Nov 6, 2025
+0dSEC Form 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
17.5K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

0
MA
Mahdessian AraDirector, Chief Executive Officer
TTANServiceTitan, Inc.
Derivative conversion · 10b5-1 plan
C—
14.3K sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC Form 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
10.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC Form 4

Evidence

0
WF
Widman FredrikVP Corporate Controller
ISRGINTUITIVE SURGICAL INC
Option exercise · 10b5-1 plan
M—
159 sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC Form 4

Evidence